Substituted Cinnoline Derivatives as BTK Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current inhibitors of Bruton's tyrosine kinase (BTK) have limitations in effectively treating diseases associated with BTK, such as lymphoma, inflammatory disorders, and autoimmune diseases, as they may not provide comprehensive therapeutic benefits across various conditions.
Innovation Solution
Development of substituted cinnoline derivatives and related compounds that act as potent BTK inhibitors, formulated into pharmaceutical compositions for treating diseases, disorders, and conditions associated with BTK inhibition, including autoimmune diseases, inflammatory disorders, and cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If current BTK inhibitors are used, then some therapeutic benefit is achieved, but comprehensive therapeutic benefits across various conditions are not provided
Solution Approach 1:
The patent develops substituted cinnoline derivative compounds that function as potent BTK inhibitors applicable across multiple disease indications including lymphoma, inflammatory disorders, and autoimmune diseases. The compounds are designed to provide universal therapeutic activity against BTK-mediated pathologies, enabling a single agent to address diverse conditions that share BTK as a common pathological target.
Solution Approach 2:
The patent optimizes key pharmacological parameters of BTK inhibitors including potency (IC50 values), selectivity, and pharmacokinetic properties. By systematically modifying chemical structures of cinnoline derivatives and evaluating their biological activity, the invention achieves improved therapeutic efficacy and broader applicability across different disease models while maintaining reliable inhibition of BTK.
2Adaptability or versatility
If existing BTK inhibitors are used, then treatment for specific conditions is provided, but comprehensive treatment approach for multiple conditions is lacking
Solution Approach 1:
The substituted cinnoline derivatives are designed as multi-indication therapeutic agents that can treat lymphoma, inflammatory disorders, and autoimmune diseases through a single mechanism of BTK inhibition. This universal applicability simplifies treatment approaches by providing a single compound that addresses multiple conditions rather than requiring different agents for each indication.
3Reliability
If current inhibitors are used, then some disease progression is controlled, but complete suppression of disease progression is not achieved
Solution Approach 1:
The patent systematically optimizes the potency and selectivity parameters of BTK inhibition by modifying cinnoline derivative structures. The compounds achieve enhanced disease progression control through improved BTK inhibition potency (lower IC50 values) and better pharmacokinetic properties, resulting in more reliable and complete suppression of disease progression across multiple disease models.
Data Source
AI summary
Disclosed are compounds of Formula 1,and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are defined in the specification. The compounds are inhibitors of Bruton's tyrosine kinase (BTK). This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders or conditions associated with BTK.